Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise

by Zacks Equity Research

Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.

Jobless Claims Tick in Higher

by Zacks Equity Research

Jobless Claims Tick in Higher.

Mark Vickery headshot

Jobless Claims, Productivity Higher; TM, WEN, CROX Report

by Mark Vickery

Initial Jobless Claims came in at their highest levels in almost a year, to 249K -- well above the 235K anticipated.

Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Biogen (BIIB) delivered earnings and revenue surprises of 32% and 3.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

by Ekta Bagri

Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Countdown to Biogen (BIIB) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Biogen (BIIB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?

by Zacks Equity Research

Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical

by Zacks Equity Research

Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More

by Ekta Bagri

Sage Therapeutics (SAGE) and Agenus (AGEN) are in the spotlight following study failure and regulatory updates, respectively.

Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study

by Zacks Equity Research

Data from an early-stage study shows that treatment with Ionis' (IONS) ION582 helps improve communication, cognition and motor function in patients with Angelman syndrome, a rare nerve disorder.

SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern

by Zacks Equity Research

Sage Therapeutics' (SAGE) Zurzuvae, approved for treating postpartum depression, holds an excellent commercial opportunity. The recent pipeline setbacks are, however, an overhang.

Ionis (IONS) Completes Enrolment for Rare Disease Drug Study

by Zacks Equity Research

Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

by Zacks Equity Research

Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.

Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford

by Zacks Equity Research

Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab

by Zacks Equity Research

Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.

Denali (DNLI) Outperforms Industry in 3 Months: Here's Why

by Zacks Equity Research

Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.

FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen

by Zacks Equity Research

The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.

La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day.

Kinjel Shah headshot

Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?

by Kinjel Shah

Eli Lilly (LLY) files for the approval of tirzepatide to treat obstructive sleep apnea in adults with obesity in the United States. If approved, sales of the blockbuster drug will rise further.

Is the Options Market Predicting a Spike in Biogen (BIIB) Stock?

by Zacks Equity Research

Investors need to pay close attention to Biogen (BIIB) stock based on the movements in the options market lately.